Patent Law

The Center for Business Intelligence is hosting the above-titled conference that will include discussions on regulatory developments and strategic planning for pre-litigation, prosecuting and defending PIV suits.  The conference will take place on October 18 - 19, 2010 in Philadelphia, PA.

Paragraph IV litigation is reaching an all-time high with almost $85 billion in product sales that potentially could be affected by pending litigation and more than twenty-five drugs going off patent before 2012.  Today?s pharmaceutical companies, both brand and generic, have much at stake in this costly, complex and constantly changing area of patent litigation.  CBI?s 3rd Congress brings both sides of the issue together for two days of presentations and panel discussions to discuss litigation strategies, statutory guidelines, current cases and their landmark decisions.  This timely and valuable content is designed to provide you with the information you need to know today for better business decisions tomorrow.

Topics to be discussed include:

• Generic vs. Generic Suits
• FTC Investigations and Pay for Delays
• FDA Forfeiture Provisions
• Use Codes and Section VIII Carve Outs
• Pre-Litigation Strategy and Development
• Inequitable Conduct, At Risk Launches and Damages
• Anti-trust and PIV counterclaims
• PIV Settlements Keynote Panel

Confirmed Speakers from:

• Axinn | Veltrop | Harkrider | LLP
• Bristol-Myers Squibb
• Endo Pharmaceuticals
• Federal Trade Commission (FTC)
• Hyman, Phelps & McNamara, P.C.
• Pfizer
• Sandoz

Learn more and register here.